Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Study Examines 'Elite' Group Of HIV-Positive People Who Appear 'Protected' From Developing AIDS
An international contingent of nearly 500 researchers and physicians are taking part in the International HIV Controllers Study, which is examining "the phenomenon," in which certain people living with HIV seem "somehow protected from AIDS," the Washington Post reports. Fewer "than one in every 300 cases, or perhaps 5,000 of the more than 1 million infected Americans" living with HIV are deemed ""elite controllers" because their ability to combat the virus puts them in exceptional company among infected individuals," according to the Post. The article states, "No one knows how their bodies keep AIDS at bay. Are their immune systems exceptionally strong and effective? Do they possess some genetic trait that protects them? Or does a combination of still-unknown factors set them apart?" Researchers anticipate that studying the T cell levels - which helps determine the progression to AIDS - of the elite controllers, will enable them "to uncover what shields these rare few from AIDS. And perhaps in the process they"ll find a way to safeguard everyone else as well," the Post reports (Slack, 7/7). Don't forget to buy zoloft online no prescription.

HearAtLast Combats Hearing Loss Epidemic With Future Sonics Atrio Ear Buds
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) is pleased to announce that it has formed a strategic alliance with VitaSound to distribute Future Sonics MP3 Ear Buds. Future Sonics is the award-winning innovator of the original professional custom and universal fit earphones for personal monitoring for major tours, venues, artists, engineers, broadcasting and houses of worship worldwide.

generic viagra online


News of the day
Meridian Bioscience Receives FDA Clearance For New Rapid Campylobacter Test
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United States. Approximately 20 million stool culture tests are conducted each year in the U.S. to detect the illness, known as Campylobacteriosis. Campylobacter is most often transmitted by poorly cooked poultry or person-to-person contact.
Health Insurance

Stem Cell Industry Expert Praises, Encourages Continued Progress On Legislation To Promote Benefits Of Cord Blood

Mercedes Walton, CEO of Cryo-Cell International, one of the largest and most established family cord blood banks, is praising legislative progress to date and encouraging continued momentum for existing bills through the second half of the year. H.R. 1718, the "Family Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education and Awareness Act of 2009" would continue to build on the progress from the first half of the year to enable and promote the continued research, public awareness and tax benefits related to storing and using cord blood, all of which provide great benefit to families across America. In early March, President Obama paved the way for progress by signing an executive order to remove barriers of responsible stem cell research. Later that month, U.S. Congressman Ronald Kline sponsored H.R. 1718, a proposed bill to provide significant tax benefits for the costs associated with umbilical cord blood banking. H.R. 1718 would amend an existing tax law in order to add these services to a list of qualified medical expenses that may be paid for with pre-tax dollars, or be deducted from taxable income. The promise of continued progress came in late April, when Congresswoman Jackie Speier introduced H.R. 2107, the "Cord Blood Education and Awareness Act of 2009." The proposed legislation, which was referred to committee in early June, directs the Secretary of Health and Human Services to conduct a public education campaign on umbilical cord blood stem cells. The campaign would be aimed to develop methods to educate expectant parents about their options for banking or donating their child"s cord blood. H.R. 2107 also seeks to bring healthcare professionals up-to-date on the value of cord blood banking and would make grants available to reach crucial segments of the population, such as minority communities and families with a genetic history of treatable diseases. "This year"s encouraging volume of activity is testament to the growing acknowledgement of the benefits of stem cells, including non-controversial s such as umbilical cord blood," says Cryo-Cell CEO Mercedes Walton. "As we reach the midpoint in the year it"s a great time to reflect on the important progress that has been made, and to ensure that we maintain the positive momentum toward change that will benefit America"s families today and for decades to come." "We are encouraged and grateful on behalf of the families who may soon be able to more readily learn of the potential life-saving benefits of banking their baby"s cord blood, and have the opportunity to realize tax benefits as they would other medical costs," said Walton. "Every day, all of us at Cryo-Cell are motivated by the stories of families who have been touched by the miracle of stem cells, and by the rapid progress being made by the scientific community," adds Walton. Currently, stem cells from cord blood treat more than 75 such conditions, including sickle cell disease, several types of acute and chronic leukemias, Non-Hodgkin"s lymphoma, and Hodgkin"s disease. Emerging science shows great promise for potential treatments including spinal cord injury, heart disease, breast cancer, stroke, diabetes, Parkinson"s disease, Alzheimer"s disease and many more. A pioneer in the non-controversial stem cell arena, Cryo-Cell has served over 175,000 clients worldwide and led the cord blood banking industry with the successful establishment of a state-of-the-art Good Manufacturing Practice/Good Tissue Practice (cGMP/cGTP) laboratory processing facility well ahead of emerging regulation and competition. About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL.OB) Based in Oldsmar, Florida, with over 175,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Cryo-Cell International, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009